This listing describes afatinib 20 mg as an oral targeted anticancer medicine. Verify the manufacturer, formulation, pack size, and country-specific approved indications before publishing.
Afatinib can cause severe diarrhea, dehydration, serious skin reactions, interstitial lung disease, liver injury, eye complications, and fetal harm. Treatment requires supervision by an oncology specialist.
What Is Afatinib 20 mg?
Afatinib 20 mg is an oral targeted anticancer medicine belonging to the tyrosine kinase inhibitor class.
It is used to treat selected types of non-small cell lung cancer (NSCLC), particularly tumors with certain activating mutations in the epidermal growth factor receptor (EGFR) gene.
Afatinib works by irreversibly blocking signaling through members of the ErbB receptor family, including EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4).
These receptors are involved in cell growth, survival, and proliferation.
In susceptible cancer cells, blocking these signaling pathways may slow tumor growth and promote cancer cell death.
Afatinib is a targeted therapy, not conventional cytotoxic chemotherapy.
The 20 mg strength is commonly used when a lower dose is needed because of treatment-related adverse reactions or other patient-specific considerations.
However, the appropriate starting dose and subsequent dose adjustments must be determined by the treating oncologist.
Common Reasons for Prescribing Afatinib
- EGFR mutation-positive non-small cell lung cancer
- Selected metastatic NSCLC with susceptible EGFR mutations
- Certain uncommon EGFR mutation-positive lung cancers
- Selected previously treated metastatic squamous NSCLC
- Oncology-directed dose reduction after adverse effects
- Continued targeted therapy at an individually tolerated dose
Important: Afatinib is not effective against every lung cancer. Molecular testing and clinical assessment are essential when selecting EGFR-targeted treatment.
How Does Afatinib 20 mg Work?
1. Targets the ErbB Receptor Family
Afatinib inhibits several receptors involved in cancer cell signaling, including EGFR, HER2, and HER4.
2. Irreversibly Inhibits Tyrosine Kinase Activity
Afatinib forms covalent bonds with its target receptors, producing irreversible inhibition of their kinase activity.
3. Blocks Cancer Growth Signals
EGFR and related receptors activate pathways that regulate cell growth and survival.
Afatinib reduces signaling through these pathways in susceptible tumors.
4. Interferes With Tumor Cell Proliferation
By inhibiting receptor signaling, afatinib may reduce the ability of certain cancer cells to multiply.
5. Promotes Cancer Cell Death
In responsive cancer cells, inhibition of growth and survival pathways may contribute to cell death.
6. Targets Specific Molecular Abnormalities
The effectiveness of afatinib depends partly on the genetic characteristics of the tumor.
7. Helps Control Disease Progression
In appropriately selected patients, afatinib may delay cancer progression and help control tumor-related symptoms.
Important: Afatinib is not effective against all EGFR mutations. For example, acquired EGFR T790M resistance and EGFR exon 20 insertion mutations may require different treatment approaches.
Uses of Afatinib 20 mg
1. EGFR Mutation-Positive Non-Small Cell Lung Cancer
Afatinib is used to treat selected EGFR mutation-positive NSCLC.
Its suitability depends on the specific EGFR mutation and current oncology treatment guidelines.
2. Metastatic Non-Small Cell Lung Cancer
Afatinib is approved in certain jurisdictions for metastatic NSCLC with susceptible EGFR mutations.
3. EGFR Exon 19 Deletion-Positive NSCLC
Tumors containing certain EGFR exon 19 deletions may respond to afatinib.
4. EGFR L858R Mutation-Positive NSCLC
Afatinib may be used in selected patients with the EGFR exon 21 L858R substitution.
5. Selected Uncommon EGFR Mutations
Afatinib has activity against certain uncommon EGFR mutations, including G719X, L861Q, and S768I.
Treatment selection requires review of the exact molecular findings.
6. Previously Treated Squamous NSCLC
In the United States, afatinib has an indication for metastatic squamous NSCLC progressing after platinum-based chemotherapy.
Its current clinical role depends on available alternatives and patient-specific factors.
7. Targeted Therapy for Molecularly Selected Patients
Afatinib may be considered when the tumor’s molecular profile supports its use.
8. Treatment Following Intolerance to Certain Therapies
An oncologist may evaluate afatinib as an option in selected patients, depending on prior treatments, resistance mutations, and tolerability.
9. Dose-Adjusted Treatment
The 20 mg strength may be used when the oncologist determines that a reduced dose is appropriate.
10. Long-Term Disease Management
Patients who respond to and tolerate afatinib may continue treatment according to the oncology plan until disease progression or unacceptable toxicity.
Important: Afatinib is not a universal treatment for lung cancer, and newer EGFR-targeted therapies may be preferred in many treatment settings.
Afatinib 20 mg Dosage and Administration
Afatinib dosing must be determined by an oncology specialist.
General Reference Dosage
| Dosage Information | Details |
|---|---|
| Tablet Strength | 20 mg |
| Active Ingredient | Afatinib |
| Administration Route | Oral |
| Common Adult Starting Dose | 40 mg once daily for certain approved indications |
| 20 mg Tablet Role | Commonly used for dose reduction or other specialist-directed adjustments |
| Administration Frequency | Usually once daily |
| Food Instructions | Take on an empty stomach |
| Treatment Duration | Until disease progression or unacceptable toxicity, as directed |
| Dose Adjustments | Based on adverse reactions, kidney function, and other clinical factors |
| Medical Supervision | Required throughout treatment |
Important: Afatinib 20 mg is not automatically the standard starting dose. The appropriate regimen depends on the indication, kidney function, tolerability, and approved product instructions.
General Administration Instructions
- Take afatinib exactly as prescribed by the oncologist.
- Take it at approximately the same time each day.
- Swallow the tablet whole with water.
- Take it on an empty stomach.
- Avoid eating for at least 3 hours before and 1 hour after the dose.
- Do not crush or chew the tablet.
- Do not change the dose without medical advice.
- Report diarrhea promptly.
- Monitor for new breathing difficulties or severe skin reactions.
- Attend scheduled oncology appointments and laboratory tests.
- Inform the oncology team about all other medicines and supplements.
- Follow the prescribed treatment schedule consistently.
Should Afatinib Be Taken With Food?
Afatinib should generally be taken on an empty stomach.
Food can reduce afatinib exposure.
The usual instructions are to avoid food for at least 3 hours before and 1 hour after taking the medicine.
What If a Dose Is Missed?
If a dose is missed, follow the product instructions.
For the reference afatinib labeling, a missed dose may be taken if the next scheduled dose is more than 12 hours away.
If the next dose is within 12 hours, skip the missed dose.
Do not take two doses together.
What If Too Much Afatinib Is Taken?
Contact the oncology team or seek urgent medical advice.
Do not attempt to compensate for an overdose by independently changing future doses.
Can Afatinib Be Stopped Suddenly?
Do not independently stop treatment.
The oncology team may temporarily interrupt, reduce, or discontinue afatinib because of adverse effects, disease progression, or other clinical considerations.
How Long Does Afatinib 20 mg Take to Work?
Afatinib begins inhibiting its molecular targets after absorption.
However, measurable cancer treatment responses generally require time.
An oncologist may evaluate the response through imaging studies and clinical assessments after several weeks of treatment.
The timing depends on the tumor’s molecular characteristics, disease burden, and individual response.
Some patients experience symptom improvement before a formal imaging assessment, but symptom changes alone do not establish treatment effectiveness.
Common Side Effects
Possible side effects include:
- Diarrhea
- Acne-like skin rash
- Dry skin
- Itching
- Mouth sores
- Stomatitis
- Reduced appetite
- Nausea
- Vomiting
- Nail inflammation
- Paronychia
- Fatigue
- Weight loss
- Nosebleeds
Diarrhea and skin reactions are particularly important adverse effects of afatinib.
Potentially Harmful Effects & Serious Health Risks
1. Severe Diarrhea
Afatinib can cause severe diarrhea that may lead to dehydration and electrolyte disturbances.
2. Dehydration
Persistent diarrhea or vomiting may cause significant fluid loss.
3. Kidney Injury
Dehydration associated with severe diarrhea may contribute to acute kidney injury.
4. Severe Skin Reactions
Afatinib may cause significant acneiform rash, blistering, or other serious skin reactions.
5. Interstitial Lung Disease
Afatinib can cause interstitial lung disease or pneumonitis, which may be life-threatening.
6. Liver Injury
Elevated liver enzymes and serious liver injury have been reported.
7. Severe Stomatitis
Painful mouth inflammation and ulcers may interfere with eating and drinking.
8. Eye Complications
Keratitis and other ocular complications may occur.
9. Cardiac Dysfunction
Decreased left ventricular ejection fraction has been reported with afatinib.
10. Electrolyte Disturbances
Severe diarrhea and dehydration may cause abnormalities in electrolyte levels.
11. Severe Nail and Skin Inflammation
Paronychia and other skin complications may become painful or infected.
12. Fetal Harm
Afatinib may harm an unborn baby.
13. Treatment Interruption Due to Toxicity
Severe adverse reactions may require temporary interruption, dose reduction, or permanent discontinuation.
14. Serious Allergic Reactions
Hypersensitivity reactions may occur.
Emergency warning: Seek urgent medical assessment for new or worsening shortness of breath, severe persistent diarrhea, dehydration, blistering skin reactions, severe eye pain, or symptoms suggesting liver injury.
Contraindications & Safety Precautions
1. Allergy to Afatinib
Patients with known hypersensitivity to afatinib or formulation ingredients should not use the product without specialist assessment.
2. Severe Diarrhea
Report diarrhea promptly. Early management is important because dehydration can become serious.
3. Dehydration Risk
Maintain fluid intake according to the oncology team’s instructions and seek assessment for persistent vomiting or diarrhea.
4. Kidney Disease
Kidney function should be assessed because afatinib exposure may increase in patients with significant renal impairment.
5. Liver Disease
Patients with liver impairment require appropriate clinical assessment and monitoring.
6. Interstitial Lung Disease
New cough, fever, or worsening breathlessness may indicate serious pulmonary toxicity.
7. Skin Disorders
Patients should report severe or worsening rash, blistering, or painful skin changes.
8. Sun Exposure
Afatinib-associated skin reactions may worsen with sun exposure.
Appropriate sun protection may be recommended.
9. Eye Problems
Report eye pain, redness, light sensitivity, excessive tearing, or changes in vision.
10. Heart Disease
Patients with cardiac disease may require additional monitoring.
11. Pregnancy
Afatinib can cause fetal harm and should not be used during pregnancy unless the oncology specialist determines that treatment is essential.
12. Contraception
Patients who can become pregnant should use effective contraception during treatment and for the period specified in the approved product labeling after the final dose.
13. Breastfeeding
Breastfeeding is not recommended during treatment and for the period specified by the applicable product label after treatment.
14. Children
The safety and effectiveness of afatinib have not been established for routine pediatric use.
15. Older Adults
Older patients may require closer monitoring because of adverse effects and other medical conditions.
16. Drug Interactions
Potentially important interactions include:
- P-glycoprotein (P-gp) Inhibitors: May increase afatinib exposure.
- P-gp Inducers: May reduce afatinib exposure.
- Rifampicin: May reduce afatinib concentrations.
- Certain Antifungals: Some may affect afatinib exposure through transporter interactions.
- Certain Antibiotics: Some may affect drug transporter activity.
- Other Anticancer Medicines: Require specialist review.
- Herbal Supplements: May affect drug exposure or tolerability.
17. Food Interactions
Afatinib should be taken on an empty stomach according to the product instructions.
18. Medical Monitoring
Healthcare professionals may monitor:
- Complete blood count when clinically indicated
- Kidney function
- Liver function
- Electrolytes
- Diarrhea severity
- Hydration status
- Skin reactions
- Mouth inflammation
- Eye symptoms
- Pulmonary symptoms
- Cardiac function when indicated
- Body weight
- Treatment response
- Imaging findings
- Need for dose reduction or interruption
Advantages
- Oral targeted anticancer therapy.
- Irreversible ErbB family inhibition.
- Activity against selected EGFR-mutated NSCLC.
- Used in certain metastatic lung cancer treatment regimens.
- Activity against some uncommon EGFR mutations.
- May help delay disease progression in responsive tumors.
- May reduce tumor burden.
- Does not require intravenous administration.
- Once-daily dosing in standard regimens.
- 20 mg strength supports dose adjustments.
- Established clinical evidence for selected indications.
- May be continued while clinically effective and tolerable.
Disadvantages / Limitations
- Not effective against every lung cancer.
- Requires molecular testing for many indications.
- May cause severe diarrhea.
- May cause dehydration.
- May cause kidney injury.
- May cause severe skin rash.
- May cause mouth ulcers.
- May cause nail inflammation.
- May cause reduced appetite.
- May cause weight loss.
- May cause liver injury.
- May cause interstitial lung disease.
- May cause eye complications.
- May affect cardiac function.
- Can harm an unborn baby.
- Requires oncology monitoring.
- May interact with certain medicines.
- Must be taken on an empty stomach.
- May require dose reduction.
- Resistance to treatment can develop.
- Newer targeted therapies may be preferred in certain settings.
Important Notes
Generic Name: Afatinib.
Strength: 20 mg.
Drug Class: Tyrosine Kinase Inhibitor.
Therapeutic Category: Targeted Anticancer Medicine.
Primary Use: Selected EGFR mutation-positive NSCLC.
Additional Use: Selected previously treated metastatic squamous NSCLC.
Mechanism: Irreversible inhibition of ErbB receptor tyrosine kinases.
Administration Route: Oral.
Reference Starting Dose: Commonly 40 mg once daily for certain approved indications.
20 mg Strength: Commonly used for specialist-directed dose adjustment.
Food Instructions: Take on an empty stomach.
Major Warning: Severe diarrhea, dehydration, skin reactions, interstitial lung disease, liver injury, and fetal harm.
Pregnancy Warning: Can cause fetal harm.
Breastfeeding Warning: Not recommended during treatment.
Monitoring: Kidney function, liver function, hydration, adverse effects, and treatment response.
Prescription Status: Prescription-Only Anticancer Medicine.
Storage: Follow manufacturer instructions.
Frequently Asked Questions
1. What is Afatinib 20 mg used for?
Afatinib 20 mg is a targeted anticancer medicine used in selected treatment regimens for non-small cell lung cancer.
2. Is Afatinib a chemotherapy medicine?
Afatinib is a targeted anticancer medicine, not conventional cytotoxic chemotherapy.
3. How does Afatinib work?
It irreversibly inhibits certain ErbB family receptor tyrosine kinases, reducing growth and survival signaling in susceptible cancer cells.
4. Can Afatinib treat lung cancer?
Yes. It is used for selected types of non-small cell lung cancer, particularly tumors with susceptible EGFR mutations.
5. Does Afatinib work for every EGFR mutation?
No. Its effectiveness depends on the specific mutation, and some mutations are resistant.
6. Is Afatinib 20 mg the standard starting dose?
Not usually. A common starting dose for certain approved indications is 40 mg once daily, while 20 mg is often used for dose adjustment.
7. How should Afatinib 20 mg be taken?
Take it orally according to the oncologist’s instructions, usually once daily on an empty stomach.
8. Can Afatinib be taken with food?
Afatinib should generally be taken at least 3 hours after food and at least 1 hour before the next meal.
9. Can Afatinib cause diarrhea?
Yes. Diarrhea is a common and potentially serious adverse effect.



































































William (verified owner) –
Works wonders for boosting my immune system naturally.
Angel (verified owner) –
Noticeable immune boost, I feel more resilient against viruses.